Premium
Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy
Author(s) -
Sadee W,
Wang D,
Papp AC,
Pinsonneault JK,
Smith RM,
Moyer RA,
Johnson AD
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.314
Subject(s) - pharmacogenomics , rna splicing , single nucleotide polymorphism , computational biology , rna , biology , drug , genetics , pharmacogenetics , bioinformatics , medicine , pharmacology , genotype , gene
The use of pharmacogenomic biomarkers can enhance treatment outcomes. Regulatory polymorphisms are promising biomarkers that have proven difficult to uncover. They come in two flavors: those that affect transcription (regulatory single‐nucleotide polymorphisms (rSNPs)) and those that affect RNA functions such as splicing, turnover, and translation (termed structural RNA SNPs (srSNPs)). This review focuses on the role of srSNPs in drug metabolism, transport, and response. An understanding of the nature and diversity of srSNPs and rSNPs enables clinical scientists to evaluate genetic biomarkers. Clinical Pharmacology & Therapeutics (2011) 89 3, 355–365. doi: 10.1038/clpt.2010.314